BCL2 and hematologic disorder: Venetoclax, also known as ABT-199, is a selective BCL2 protein inhibitor approved by the FDA for the treatment of chronic lymphocytic leukemia as monotherapy therapy, and in combination therapies for other hematologic malignancies [18, 19].